Table 3.
Patient-reported outcomes at baseline and postdisclosure among participants who had multigene testing
| Scale | Score range | Telephone disclosure (n = 87) |
In-person disclosure (n = 82) |
TD-IPD difference in change (95% CI) | ||||
|---|---|---|---|---|---|---|---|---|
| Baseline Mean (SD) | Post disclosure Mean (SD) | Change score (SD) | Baseline Mean (SD) | Post disclosure Mean (SD) | Change score (SD) | |||
| Genetic knowledge | 6–28 | 22.92 (2.28) | 23.08 (2.34) | +0.14 (1.93) | 22.28 (2.29) | 22.75 (2.63) | +0.43 (2.32) | –0.29 (–0.95 to 0.36) |
| Multigene knowledge | 11–54 | 36.22 (5.11) | 37.21 (4.03) | +0.75 (6.07) | 37.46 (4.07) | 36.92 (4.30) | –0.45 (4.93) | 1.20 (–0.52 to 2.91) |
| State anxiety | 20–80 | 32.60 (12.50) | 32.66 (12.33) | +0.06 (9.98) | 33.78 (12.90) | 33.0 (10.59) | –0.78 (8.4) | 0.84 (–1.96 to 3.65) |
| General anxiety | 0–21 | 6.30 (3.71) | 5.87 (3.65) | –0.43 (2.31) | 6.67 (3.27) | 5.74 (3.50) | –0.92 (2.19) | 0.49 (–0.20 to 1.17) |
| Depression | 0–21 | 2.55 (3.03) | 2.54 (2.96) | –0.01 (2.19) | 2.83 (2.93) | 2.75 (2.78) | –0.07 (1.87) | 0.06 (–0.56 to 0.68) |
| Cancer-specific distress | 0–70 | 15.89 (13.07) | 15.98 (13.44) | +0.09 (11.17) | 17.64 (13.64) | 17.54 (13.24) | –0.36 (9.38) | 0.44 (–2.71 to 3.60) |
| Satisfaction | 9–45 | 39.26 (4.07) | 40.11 (4.62) | +0.85 (4.27) | 39.57 (4.02) | 40.50 (4.24) | +1.02 (4.91) | –0.17 (–1.57 to 1.24) |
| Behavioral intention items* | ||||||||
| Planning screening mammogram | 1–7 | 6.41 (1.58) | 6.64 (1.24) | +0.19 (1.66) | 6.50 (1.19) | 6.36 (1.61) | –0.20 (1.47) | 0.39 (–0.20 to 0.97) |
| Planning screening breast MRI | 1–7 | 4.57 (2.28) | 4.82 (2.29) | 0 (1.99) | 4.06 (2.33) | 4.21 (2.44) | –0.15 (1.98) | 0.15 (–0.73 to 1.02) |
| Planning prophylactic mastectomy | 1–7 | 2.71 (1.92) | 2.50 (2.14) | –0.27 (2.48) | 2.60 (1.69) | 2.08 (1.75) | –0.66 (1.53) | 0.39 (–0.61 to 1.38) |
| Planning prophylactic oophorectomy | 1–7 | 3.34 (1.95) | 2.96 (2.14) | –0.72 (1.95) | 2.98 (1.61) | 2.63 (1.96) | –0.73 (1.89) | 0.01 (–0.90 to 0.90) |
| Planning colonoscopy | 1–7 | 3.47 (2.51) | 3.57 (2.49) | +0.08 (2.15) | 3.44 (2.42) | 3.61 (2.51) | 0 (1.94) | 0.08 (–0.70 to 0.86) |
*
Patients could respond “not applicable” if screening behavior had not been recommended for them; mammogram (n = 58 TD, n = 56 IPD); breast MRI (n = 40 TD, n = 41 IPD); prophylactic mastectomy (n = 33 TD, n = 35 IPD); prophylactic oophorectomy (n = 40 TD, n = 33 IPD); colonoscopy (n = 49 TD, n = 60 IPD). There were no statistically significant differences in baseline characteristics between arms in the subset of patients who had multigene panel testing. CI = confidence interval; IPD = in-person disclosure; MRI = magnetic resonance imaging; TD = telephone disclosure.